KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin (2016 - 2025)

Supernus Pharmaceuticals has reported EBT Margin over the past 15 years, most recently at 0.9% for Q4 2025.

  • Quarterly EBT Margin fell 1605.0% to 0.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.82% through Dec 2025, down 2161.0% year-over-year, with the annual reading at 6.82% for FY2025, 2161.0% down from the prior year.
  • EBT Margin was 0.9% for Q4 2025 at Supernus Pharmaceuticals, up from 30.17% in the prior quarter.
  • Over five years, EBT Margin peaked at 25.58% in Q3 2024 and troughed at 30.17% in Q3 2025.
  • The 5-year median for EBT Margin is 6.54% (2023), against an average of 6.01%.
  • Year-over-year, EBT Margin skyrocketed 2826bps in 2024 and then tumbled -5575bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 1.29% in 2021, then soared by 1529bps to 21.0% in 2022, then tumbled by -97bps to 0.6% in 2023, then surged by 2414bps to 15.15% in 2024, then plummeted by -106bps to 0.9% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBT Margin are 0.9% (Q4 2025), 30.17% (Q3 2025), and 10.07% (Q2 2025).